Scheme, which subsidises the cost of the drugs. Nevertheless, by 2016 use of medical abortion was substantially less than anticipated, 2 and obtaining medical abortion remains difficult for many Australian women.
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To address this problem, the Tabbot Foundation, based in Sydney, New South Wales, launched a direct-to-patient telemedicine service in June 2015 to enable women to obtain medical abortion without visiting a medical practitioner. In this paper, we present observations from the first 18 months of this service.
MATERIALS AND METHODS

The Tabbot Foundation Service
The specific procedures for providing abortion evolved somewhat over the course of the first 18 months (http://www.tabbot.com.
au/). A basic description of the service follows.
Each woman who contacted the Foundation was screened by telephone to confirm that she desired an abortion and met preliminary criteria. These criteria included the following: she had a positive pregnancy test, was <8 weeks gestation by menstrual dating, lived ≤60 minutes from a medical facility, had no major medical illnesses or history of severe dysmenorrhea, identified someone to be with her during treatment, spoke English and could pay by electronic fund transfer. In addition, because laws in the Australian Capital Territory, Northern Territory and South
Australia specified that abortions must be performed in an approved medical facility, women from those jurisdictions were required to have an address in another state where they could receive and ingest the abortifacients.
If preliminary criteria were met, Foundation staff referred the patient to facilities of her choice for a screening ultrasound, hae- In the first year of the service, the standard abortifacient regimen was mifepristone 200 mg orally followed 40-45 h later by misoprostol 800 μg buccally. In August 2016, all patients were provided with additional misoprostol 200 μg to take sublingually thrice daily for two days. A specific combination of analgesics,
anti-emetics and an antibiotic was also recommended.
Analysis
De-identified information was transferred from the electronic medical record into an analysis database. Some data from six patients were obviously invalid: three patients had recorded dates of registration, drug shipment authorisation and misoprostol ingestion that did not occur in that order, one had an interval of 273 days between registration and drug shipment authorisation, and two had intervals of ≥274 days between registration and ultrasound.
Our analyses considered these dates as missing. Patients' addresses were classified according to the 2011 Australian Statistical Geography Standard Remoteness Area classification, which reflects relative access to services. 6 For this analysis, we defined a complete medical abortion as one that met any of these criteria:
serum HCG concentration declined by ≥80%, urine pregnancy test was negative, ultrasound showed complete abortion, or a clinician diagnosed complete abortion without surgery. We defined a patient to have had full follow-up if she had had a complete medical abortion according to the analysis definition, a uterine evacuation, or an ongoing pregnancy that she planned to continue. We used descriptive statistics to describe the women who accessed the service, the process indicators and the outcomes. We used χ 2 tests to test associations between remoteness area classification and source of initial introduction to the service and between abortifacient regimen and outcomes. We considered a P-value <0.05 as statistically significant. The Allendale Investigational Review Board (Old Lyme, CT, USA) approved the analysis. The Foundation provided medications to 1010 of the 1409 registrants (72%). The characteristics of these women were similar to those of the full registrant population (Table 1 ). All women who were sent packages had recorded gestational ages of <63 days by ultrasound at drug shipment authorisation, except one whose recorded gestational age was 66 days and four whose gestational ages were unavailable. Nearly all (970/1010; 96%) had at least one contact with Foundation staff after drug shipment authorisation.
RESULTS
Between
Progress through the process was efficient (Table 2) . Patient evaluation and drug shipment authorisation were completed within 15 days for more than 95% of women who ultimately received medications. This interval was shorter for the 16% of women who had ultrasounds before registration than for those who had ultrasounds on or after registration (median three vs seven days, respectively). Of the 962 women who had a valid date of misoprostol ingestion recorded, nearly all took the drug within 10 days after drug shipment authorisation. Sixteen women reported having taken the misoprostol at gestational ages of more than 63 days, but all were less than 70 days.
Of the 1010 women who were sent medications, 31 (3%) provided no relevant information after shipment, and 14 (1%) reported that they did not take the misoprostol. Most of the latter group reported that they had either miscarried or decided not to have a medical abortion. Of the other 965 women, full follow-up according to our analysis definition was accomplished in 754 (78%). Of those, 96% had a complete abortion without surgical uterine evacuation, and 95% had no face-to-face clinical encounter (other than for providing the HCG specimen) after the package was sent (Table 3) . Neither abortion outcomes nor the incidence of face-to-face encounters changed significantly after the intro- Women were asked at the last contact to rate their satisfaction with the process. Of the 802 who responded, 781 (97%) rated it a 1 (highly satisfied) on a scale of 1-5.
DISCUSSION
Telemedicine is increasingly recognised as an important approach for increasing access to abortion and for enhancing patients' privacy and autonomy. Gestational age in days by ultrasound on day of misoprostol ingestion ‡ 962 33 51 62 69 †Table excludes three cases in which registration, drug prescription and misoprostol ingestion if any were not recorded as having occurred in that order and one case in which an interval of 273 days was recorded between these dates.
‡Row excludes 44 who did not take misoprostol or provided no relevant information after shipment. §Row excludes 44 who did not take misoprostol or provided no relevant information after shipment, 12 whose last contacts were on the day of misoprostol ingestion, and two whose last contacts were recorded as having occurred >100 days after misoprostol ingestion. 3 Nearly all patients were highly satisfied.
The service was used disproportionately by women outside of major cities: 60% of women who received abortion drugs from the Foundation lived in regional and remote communities, compared to 29% of the Australian population (Fig. 1) .
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This finding is encouraging because these communities are underserved by abortion clinics 5, 16, 17 and constitute a priority population group for health interventions in Australia.
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Notably, whereas most registrants from major cities discovered the service from internet websites, fewer than half of non-urban women did so; for the latter group, referrals from medical providers were relatively more important. Ensuring that health professionals in non-urban settings inform patients about the option of telemedicine is key to realising its potential for enhancing service in these areas.
One limitation of our study is that only 76% of the women who were sent medications either had full follow-up according to our analysis definition or reported not having taken the misoprostol. This proportion is somewhat lower than the 87% reported in a recent series of in-person medical abortions in Australia.
14 Also, information about outcomes after face-to-face encounters was incomplete. However, 96% of patients had at least one posttreatment contact with the Foundation, and every patient was sent a urine pregnancy test to perform at home four weeks after treatment. Symptom-based follow up with or without pregnancy testing has been validated in several studies 19, 20 and is now rou- 
Termination of Pregnancy Law Reform Act in the Northern
Territory, which removed the requirement that abortion must be provided in hospitals, in-home abortion through one or both services is now available to over 93% of women in the country, excluding only those in South Australia. We hope that Australia will serve as a model for other nations desiring to use telemedicine to increase access to abortion care.
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